ABSTRACT
PURPOSE We aimed to quantify the sublocal geometric uncertainties of the neck prophylactic clinical target volume (CTVprophy) during image-guided radiotherapy for nasopharyngeal cancer (NPC).
MATERIALS AND METHODS Twenty patients with locally advanced NPC underwent one planning computed tomography (CTplan) followed by six weekly CT (CTrepeat) scans during chemotherapy and intensity-modulated radiation therapy. The sternocleidomastoid muscle (SCM) and its anterior, middle, and posterior parts, as well as the body contours at the 1st (C1) and 2nd (C2) cervical vertebrae, hyoid bone (HB), and cricoid cartilage (CC) in transverse CT sections, were manually delineated in the CTplan and each CTrepeat. The residual error and 2D or 3D vector displacements of each sublocation were calculated, and the planning target volume (PTV) margins were estimated using the PTV margin formula.
RESULTS The left- and right-sided SCM volume decreased by 3.7 ± 9.6% (1.9–5.4%) and 5.1 ± 6.7% (3.9–6.3%), respectively, and the center of mass shifted medially 0.8–0.9 mm. An anisotropic PTV margin of 2–4 and 1–5 mm was needed in the left-right and anterior-posterior directions, respectively. The geometric changes in the upper neck at the C1 and C2 sections were smaller than those in the middle-lower neck at the HB and CC levels. At the same sublocation, the margin needed in the anterior-middle part was smaller than that needed in the posterior part of the neck. The rigid imaging registration-induced anatomical errors in the upper neck were < 1.9%, and those in the middle and lower neck level were 0.6–3.8%.
CONCLUSIONS The surface geometrical changes of the neck prophylactic CTV in the sublocations are substantial and an anisotropic PTV margin of 1–5 mm is needed in the context of image-guided radiotherapy for NPC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Natural Science Funding of China (81974462).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of Hubei Cancer Hospital, Wuhan, China. And research data are stored in an institutional repository and will be shared upon request to the corresponding author.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest All authors declare no conflicts of interest. This work was presented at the 60th annual meeting of the American Society of Radiation Oncology, San Antonio, Texas, USA, October 21 - 24, 2018.
Funding This work was funded by National Natural Science Funding of China (81974462).
Data availability Research data are stored in an institutional repository and will be shared upon request to the corresponding author
Data Availability
All data produced in the present study are available upon reasonable request to the authors
